Indaptus Therapeutics, Inc. 8-K

What Happened
Indaptus Therapeutics (INDP) filed an 8-K reporting that Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and that the Board appointed Yu Ding as the Company’s new Chief Financial Officer effective April 1, 2026. The filing states Mr. Sassi’s resignation was not due to any disagreement with the Company. Separately, the Board appointed Qinglai Lu as a director on March 31, 2026, effective April 8, 2026, and determined he qualifies as an independent director under Nasdaq rules.

Key Details

• CFO change: Nir Sassi resigned effective April 1, 2026; Yu Ding, age 51, appointed CFO effective April 1, 2026.
• Director appointment: Qinglai Lu, age 48, appointed to the Board effective April 8, 2026; deemed independent by the Board.
• Audit Committee: Matthew McMurdo resigned from the Audit Committee; Qinglai Lu and Jerome Jabbour were appointed to the Audit Committee.
• Background highlights: Mr. Lu has 20+ years in corporate finance, private credit and asset management (Plunkett Capital, Goldman Sachs) and is a CFA charterholder; Mr. Ding has 20+ years in finance roles including CFO positions for publicly traded companies in China/Hong Kong and holds an MBA.

Why It Matters
For investors, a CFO transition is material because the CFO leads financial reporting, controls, and investor communications—areas that affect transparency and forecasting. The addition of an independent director with extensive finance and capital-markets experience and the reshuffling of Audit Committee members can affect corporate governance and oversight of financial reporting. The company disclosed the resignation was not due to disagreement, and provided professional backgrounds for the new appointees to help investors assess continuity and governance.